(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 43MM | +4% |
Gross Profit | 26.3MM | +6% |
Cost Of Revenue | 16.6MM | +1% |
Operating Income | -63.8MM | - |
Operating Expenses | 90.1MM | - |
Net Income | -63MM | - |
R&D | 7.6MM | -3% |
G&A | 20.3MM | -18% |
Amortization | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2023 Earnings Call Transcript March 13, 2024 Anika Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-4.3 EPS, expectations were $-0.26. ANIK isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good evening, ladies and […]
Anika Therapeutics ( NASDAQ:ANIK ) Full Year 2023 Results Key Financial Results Revenue: US$166.7m (up 6.7% from FY...
Q4 2023 Anika Therapeutics Inc Earnings Call
Revenue growth and adjusted EBITDA1 exceeded expectations in the fourth quarter and full year OA Pain Management achieved record annual revenues of $102 million, up 11% in 2023 Announces cost reduction initiatives providing annualized savings of approximately $10 million Anika positioned to generate adjusted EBITDA1 of $25 to $30 million in 2024, up over 75% at the midpoint, representing an adjusted EBITDA1 margin of at least 15% BEDFORD, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Anika Therapeut
BEDFORD, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on March 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.14, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-execut
Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2023 financial results after the close of the market on Wednesday, March 13, 2024 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing
Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...